Enteric Autoantibodies and Gut Motility Disorders

Kashyap, Purna C.; Farrugia, Gianrico

doi:10.1016/j.gtc.2008.02.005

Cited by 45 publications

(37 citation statements)

References 60 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The UNC-OSU group evaluated the prevalence of anti-ENS autoimmune antibodies and the antigens recognized by the antibodies in patients diagnosed with idiopathic IBS. The approach was based on one used productively for evaluation of anti-enteric neuronal antibodies in patients with gastrointestinal disorders associated with a paraneoplastic syndrome [37][38][39][40][41][42].…”

Section: Autoimmune Neuropathymentioning

confidence: 99%

Enteric Nervous System: Neuropathic Gastrointestinal Motility

Wood

2016

Dig Dis Sci

View full text Add to dashboard Cite

Section: Autoimmune Neuropathymentioning

confidence: 99%

Enteric Nervous System: Neuropathic Gastrointestinal Motility

Wood

2016

Dig Dis Sci

View full text Add to dashboard Cite

“…Finally, if the clinical picture is highly suggestive of an occult malignancy despite a negative initial work-up, bronchoscopy or mediastinoscopy may be offered to the patient. 1 In the case of our patient, his initial chest CT was negative except for a few enlarged precarinal lymph nodes. It was decided that a lymph node biopsy would be offered to the patient if the PET scan failed to show a source.…”

Section: Management (Cancer Workup) and Treatmentmentioning

confidence: 51%

“…These autoantibodies are thought to target tumor antigens that show cross-reactivity with myenteric neurons. 1 Small cell lung carcinoma and thymoma are the most common neoplasms associated with paraneoplastic intestinal dysmotility due to ANNA-1 or anti-Hu antibodies. 4,5,15 However, associaton with lymphomas and tumors of the breast, prostate and ovary have also been reported.…”

Section: Clinical Characteristics/differential Diagnosis/serological mentioning

confidence: 99%

GI Dysmotility: A Case Report

Osley¹,

Leung²

2010

TMF

View full text Add to dashboard Cite

A 75-year-old male, with a medical history of diabetes, hypertension, coronary artery disease, status post coronary artery bypass graft, and left-sided breast cancer, status post left breast mastectomy, was transferred from an outside hospital with complaints of a month of constipation, nausea and vomiting. The patient presented to an OSH a month prior with recent onset of constipation, with no bowel movements for 10 days, changed from his usual habit of daily bowel movements. He initially responded to lactulose with a bowel movement and was discharged on a regimen of stool softeners and laxatives; however, upon returning home, he was again unable to move his bowels despite his bowel regimen and developed diffuse abdominal pain, nausea and vomiting secondary to distension. An outpatient esophagogastroduodenoscopy (EGD) showed that the patient had a normal esophagus and a large amount of retained food in the stomach, concerning for gastroparesis. This finding was thought to be secondary to his diabetes, despite his well-controlled blood sugars and a hemoglobin A1c of 7.0 %. After two further weeks of constipation, the patient was readmitted to the OSH with abdominal pain, intractable nausea and vomiting, as well as a 20-25 lbs weight loss since his symptoms began. Imaging showed colonic gaseous distention, with the cecum dilated to 9.5 cm, and an un-prepped sigmoidoscopy was performed, showing no inflammation, polyps or masses; of note, a screening colonoscopy done 4 months prior identified and removed multiple benign polyps. A CT scan of his abdomen and pelvis also did not show any obstructing colonic masses. He was presumed to have colonic pseudo-obstruction, or Ogilvie Syndrome. Erythromycin was started without effect. He was subsequently given neostigmine, which was also unsuccessful in relieving his symptoms. The patient was then referred to another OSH for further workup. A 4-day gut motility study showed a pan-GI dysmotility disorder. Furthermore, a gastric emptying study revealed markedly delayed gastric emptying of both solid and liquid foods, but defecography was entirely normal. Non-contrast CTs of the chest, abdomen and pelvis again did not identify any masses or bowel obstruction, but did show enlarged precarinal lymph nodes and prostatomegaly, as well as small thyroid nodules bilaterally. As the patient continued to fail to have a bowel movement and could not tolerate a diet, he was started on total parenteral nutrition and was transferred to Thomas Jefferson University Hospital (TJUH) for further evaluation.On presentation to TJUH, the patient complained of occasional diffuse abdominal pain and distention, as well as nausea. He had not had any vomiting since he stopped eating when he was started on TPN. He denied any swallowing difficulty but did complain of constantly spitting up clear sputum. He had not had a bowel movement in more than 4 weeks since his initial response to lactulose at the first OSH. He had lost 30 lbs in the 4 weeks since his symptoms began. His review of systems was other wise...

show abstract

“…Esta se manifiesta como pseudoacalasia (102), gastroparesia y pseudoobstrucción intestinal (38,103,104). La gastroparesia es la más común (105), a diferencia de la pseudoacalasia paraneoplásica, que es muy rara (1 persona en cada 750 000) (106).…”

Section: Síndromes Paraneoplásicos Gastrointestinalesunclassified

Síndromes paraneoplásicos en tumores gastrointestinales. Revisión de tema

Paez

Regino

et al. 2017

Rev. Colomb. Gastroenterol.

View full text Add to dashboard Cite

ResumenLos síndromes paraneoplásicos representan manifestaciones clínicas que producen los tumores en sitios distantes a ellos y que no están relacionadas físicamente con ellos ni con sus metástasis. Diferentes tumores gastrointestinales pueden presentar síndromes o manifestaciones sistémicas, dermatológicas, hematológi-cas, renales y neurológicas, entre otras. Aquí se ofrece una revisión de esas distintas manifestaciones. Palabras claveSíndrome paraneoplásico, gastrointestinal, tumores. AbstractParaneoplastic syndromes produce tumors at sites distant from themselves and are not physically related to those tumors or to their metastases. Various gastrointestinal tumors may present syndromes or systemic, dermatological, hematological, renal, neurological and other manifestations. This study reviews these manifestations. KeywordsParaneoplastic syndrome, gastrointestinal, tumors.Revisión de tema DOI: https://doi.org/10.22516/25007440.155 INTRODUCCIÓNLos síndromes paraneoplásicos (SPN) son un grupo heterogéneo de manifestaciones clínicas que se producen cuando un tumor provoca un daño en un órgano o sistema distante y que no están relacionadas físicamente con el tumor o sus metástasis (1). Esas alteraciones son independientes del efecto local del tumor, la invasión a otros órga-nos, los déficits nutricionales y las consecuencias derivadas del tratamiento antineoplásico (1, 2). La gran variedad de manifestaciones clínicas es secundaria a la liberación de sustancias por parte de las células neoplásicas malignas (2) que liberan hormonas, péptidos similares a hormonas, factores de crecimiento y citoquinas (1, 2, 3). Adicionalmente, también participan respuestas inmunitarias que, inicialmente, estaban dirigidas contra las nuevas sustancias o antígenos tumorales (oncoantígenos) y que, por reacción cruzada, terminan lesionando tejidos normales (3, 4) y, finalmente, acumulando complejos inmunes (5). Los diferentes SPN se dividen según el órgano o sistema al que afecten y, clásicamente, se clasifican en endocrinometabólicos, dermatológicos, hematológicos, reumatológicos y neurológicos (3). En la presente revisión, se describen los SPN producidos por tumores gastrointestinales (GI).

show abstract

Enteric Autoantibodies and Gut Motility Disorders

Cited by 45 publications

References 60 publications

Enteric Nervous System: Neuropathic Gastrointestinal Motility

Enteric Nervous System: Neuropathic Gastrointestinal Motility

GI Dysmotility: A Case Report

Síndromes paraneoplásicos en tumores gastrointestinales. Revisión de tema

Contact Info

Product

Resources

About